Confidently Assess Risk in Early-Stage Cancers
The first and only tissue-free MRD test for colorectal cancer (CRC) is now covered by Medicare for CRC and now available for breast and lung cancers
Guardant Reveal™ is a revolutionary blood-only liquid biopsy test that detects circulating tumor DNA (ctDNA) for minimal residual disease (MRD) assessment in early-stage colorectal, breast, and lung cancers. In addition to detection of MRD, Guardant Reveal is also available to monitor recurrence in previously diagnosed patients. Guardant Reveal is now covered for fee-for-service Medicare patients with Stage II or III CRC whose testing is initiated within three months following curative intent therapy.
Guardant Reveal for patients with early-stage CRC, breast, and lung cancers
Post-Surgery Decision Making
Surveillance
The importance of knowing in CRC
The detection of ctDNA post-surgery for CRC patients can be a sign of the need for adjuvant chemotherapy. While 80% of Stage II CRC patients are cured with surgery alone, within 5 years approximately 10% of Stage II CRC patients and 30% of Stage III CRC patients recur.¹ Current clinicopathologic tools, like CEA, are limited in their ability to identify patients at high risk for recurrence.
In 2–3 weeks, Guardant's proprietary technology detects the presence of ctDNA mutations and methylation in blood. This blood-only test addresses the challenge of tissue insufficiency in the tumor-dependent approach that requires an initial sequencing of tumor tissue to guide cDNA detection.
91% Sensitivity in CRC²
Repeat testing in the surveillance setting offers more opportunity to detect ctDNA as an early sign of recurrence. In a study published in Clinical Cancer Research, Guardant Reveal reached 91% sensitivity to detect ctDNA in patients who had a blood draw within 4 months of recurrence.
Genomic Alterations
Methylation
Navigate with confidence
In the surveillance setting, Guardant Reveal maximizes sensitivity for detecting ctDNA by simultaneously interrogating two complementary signals, genomic alterations and DNA methylation.
Tumors evolve and mutate over time. Unlike tests that rely on a static "snapshot" of a tumor, Guardant Reveal examines a wide range of genomic and epigenomic markers through a series of planned blood draws. This process allows for sensitive monitoring for recurrence in patients.
Delivering fast, reliable test results
Guardant Reveal delivers results in 2-3 weeks, depending on tumor type, and does not require tissue to initiate, eliminating the delays associated with assays that require tissue and the challenge of inadequate tissue samples. In addition, Guardant Reveal can be initiated as soon as 3 weeks after surgery.
Access continuous support with Guardant Portal
Offering easy access to your patients’ results and support services, the Guardant Portal provides everything you need for informed treatment planning, including:
• End-to-end support to manage billing
• On-call clinical support for you and your staff
References
- Tsikitis, V.L., Larson, D.W., Huebner, M. et al. Predictors of recurrence free survival for patients with stage II and III colon cancer. BMC Cancer 14, 336 (2014). https://doi.org/10.1186/1471-2407-14-336
- Parikh A, Van Seventer E, Siravegna G, Hartwig A, et al. Minimal Residual Disease Detection using a Plasma-Only Circulating Tumor DNA Assay in Colorectal Cancer Patients. Under Review. Data on file.